XPH State Street SPDR S&P Pharmaceuticals ETF
Quote as of Oct 15, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 62.07 | Day Range | 62.76 – 64.00 |
| 52-Week Range | 47.60 – 74.35 | Volume | 137.72K |
| Avg Volume | 146.17K | AUM | $444.2M (Oct 16, 2026) |
| Expense Ratio | 0.35% | Yield (TTM) | 0.44% |
| NAV | 62.13 | Premium/Discount | +1.43% indicative |
| Inception | Jun 19, 2006 | Holdings | 62 |
| Issuer | SPDR | Exchange | AMEX |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 78464A722 | ISIN | US78464A7220 |
| Management | Passive / index-tracking (per issuer description) | ||
About this ETF
SPDR Series Trust - SPDR S&P Pharmaceuticals ETF is an exchange traded fund launched by State Street Global Advisors, Inc. It is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. The fund invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Pharmaceuticals Select Industry Index, by using representative sampling technique. SPDR Series Trust - SPDR S&P Pharmaceuticals ETF was formed on June 16, 2006 and is domiciled in the United States.
Description from the fund data provider · profile as of Oct 16, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -5.64% | -6.36% | +9.70% | +12.52% | +29.91% | +18.01% | +5.64% | +4.18% | +6.71% |
| Total return | -5.64% | -6.36% | +9.81% | +12.76% | +30.45% | +19.28% | +6.94% | +5.17% | +8.47% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 15, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.35% | Annual cost of a $10,000 investment | $35.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 63 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | XERIS BIOPHARMA HOLDINGS INC | XERS | 2.69% | 1.22M | $12.4M |
| 2 | VERADERMICS INC | MANE | 2.58% | 94.10K | $11.9M |
| 3 | PACIRA BIOSCIENCES INC | PCRX | 2.58% | 326.87K | $11.9M |
| 4 | AMNEAL PHARMACEUTICALS INC | AMRX | 2.31% | 543.69K | $10.7M |
| 5 | VIATRIS INC | VTRS | 2.15% | 568.40K | $9.9M |
| 6 | ELI LILLY + CO | LLY | 2.11% | 8.33K | $9.7M |
| 7 | CORCEPT THERAPEUTICS INC | CORT | 2.08% | 81.07K | $9.6M |
| 8 | LIGAND PHARMACEUTICALS | LGND | 2.08% | 32.55K | $9.6M |
| 9 | INDIVIOR PHARMACEUTICALS INC | INDV | 2.07% | 269.74K | $9.6M |
| 10 | ANI PHARMACEUTICALS INC | ANIP | 2.07% | 132.66K | $9.5M |
| 11 | PERRIGO CO PLC | PRGO | 2.05% | 654.02K | $9.5M |
| 12 | ORGANON + CO | OGN | 2.04% | 686.07K | $9.4M |
| 13 | SUPERNUS PHARMACEUTICALS INC | SUPN | 2.03% | 222.94K | $9.4M |
| 14 | PFIZER INC | PFE | 2.03% | 337.61K | $9.4M |
| 15 | ZOETIS INC | ZTS | 2.03% | 127.93K | $9.3M |
| 16 | INNOVIVA INC | INVA | 2.01% | 443.86K | $9.3M |
| 17 | OMEROS CORP | OMER | 2.00% | 483.69K | $9.2M |
| 18 | PRESTIGE CONSUMER HEALTHCARE | PBH | 2.00% | 192.58K | $9.2M |
| 19 | MERCK + CO. INC. | MRK | 1.96% | 63.56K | $9.1M |
| 20 | JOHNSON + JOHNSON | JNJ | 1.95% | 35.12K | $9.0M |
| 21 | ELANCO ANIMAL HEALTH INC | ELAN | 1.94% | 398.24K | $9.0M |
| 22 | HARMONY BIOSCIENCES HOLDINGS | HRMY | 1.93% | 225.34K | $8.9M |
| 23 | MAZE THERAPEUTICS INC | MAZE | 1.90% | 339.49K | $8.8M |
| 24 | ETON PHARMACEUTICALS INC | ETON | 1.89% | 159.42K | $8.7M |
| 25 | ROYALTY PHARMA PLC CL A | RPRX | 1.88% | 154.79K | $8.7M |
| 26 | BRISTOL MYERS SQUIBB CO | BMY | 1.88% | 145.60K | $8.7M |
| 27 | COLLEGIUM PHARMACEUTICAL INC | COLL | 1.88% | 392.10K | $8.7M |
| 28 | JAZZ PHARMACEUTICALS PLC | JAZZ | 1.87% | 38.87K | $8.6M |
| 29 | SEPTERNA INC | SEPN | 1.85% | 231.02K | $8.5M |
| 30 | EDGEWISE THERAPEUTICS INC | EWTX | 1.84% | 216.15K | $8.5M |
| 31 | DEFINIUM THERAPEUTICS INC | DFTX | 1.83% | 246.87K | $8.4M |
| 32 | TARSUS PHARMACEUTICALS INC | TARS | 1.77% | 113.31K | $8.2M |
| 33 | MBX BIOSCIENCES INC | MBX | 1.72% | 149.07K | $7.9M |
| 34 | AMYLYX PHARMACEUTICALS INC | AMLX | 1.71% | 289.46K | $7.9M |
| 35 | HARROW INC | HROW | 1.65% | 249.76K | $7.6M |
| 36 | AXSOME THERAPEUTICS INC | AXSM | 1.64% | 44.53K | $7.6M |
| 37 | AMPHASTAR PHARMACEUTICALS IN | AMPH | 1.58% | 282.52K | $7.3M |
| 38 | ZEVRA THERAPEUTICS INC | ZVRA | 1.58% | 661.98K | $7.3M |
| 39 | TREVI THERAPEUTICS INC | TRVI | 1.57% | 563.62K | $7.2M |
| 40 | NUVATION BIO INC | NUVB | 1.54% | 1.44M | $7.1M |
| 41 | ALUMIS INC | ALMS | 1.44% | 957.01K | $6.7M |
| 42 | ENLIVEN THERAPEUTICS INC | ELVN | 1.44% | 163.25K | $6.6M |
| 43 | OCULAR THERAPEUTIX INC | OCUL | 1.33% | 817.66K | $6.1M |
| 44 | WAVE LIFE SCIENCES INC | WVE | 1.31% | 1.74M | $6.1M |
| 45 | RAPPORT THERAPEUTICS INC | RAPP | 1.28% | 198.55K | $5.9M |
| 46 | LB PHARMACEUTICALS INC | LBRX | 1.27% | 169.56K | $5.9M |
| 47 | PHIBRO ANIMAL HEALTH CORP A | PAHC | 1.25% | 154.43K | $5.8M |
| 48 | CORMEDIX INC | CRMD | 1.22% | 769.52K | $5.6M |
| 49 | AQUESTIVE THERAPEUTICS INC | AQST | 1.22% | 1.18M | $5.6M |
| 50 | ALTO NEUROSCIENCE INC | ANRO | 1.18% | 227.54K | $5.5M |
| 51 | PHATHOM PHARMACEUTICALS INC | PHAT | 1.14% | 735.04K | $5.2M |
| 52 | ACLARIS THERAPEUTICS INC | ACRS | 0.85% | 1.03M | $3.9M |
| 53 | LIQUIDIA CORP | LQDA | 0.82% | 135.69K | $3.8M |
| 54 | RELMADA THERAPEUTICS INC | RLMD | 0.81% | 1.18M | $3.7M |
| 55 | AVALYN PHARMA INC | AVLN | 0.79% | 140.93K | $3.6M |
| 56 | LEXICON PHARMACEUTICALS INC | LXRX | 0.78% | 2.05M | $3.6M |
| 57 | EYEPOINT INC | EYPT | 0.77% | 1.02M | $3.5M |
| 58 | ARVINAS INC | ARVN | 0.74% | 457.70K | $3.4M |
| 59 | EVOLUS INC | EOLS | 0.72% | 424.73K | $3.3M |
| 60 | CONTINEUM THERAPEUTICS INC A | CTNM | 0.65% | 227.80K | $3.0M |
| 61 | BIOAGE LABS INC | BIOA | 0.62% | 462.04K | $2.9M |
| 62 | SSI US GOV MONEY MARKET CLASS | — | 0.07% | 329.12K | $329.1K |
| 63 | CONTRA ESPERION THERAP | — | 0.01% | 2.23M | $44.5K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.44% | Paid (last 12 months) | $0.2747 |
| Frequency | Quarterly | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Sep 21, 2026 | Last payment | $0.0416 (Sep 23, 2026) |
| Growth 1Y | -45.79% | Growth 3Y / 5Y (ann.) | -20.81% / -1.75% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Sep 21, 2026 | Sep 21, 2026 | Sep 23, 2026 | $0.0416 |
| Jun 22, 2026 | Jun 22, 2026 | Jun 24, 2026 | $0.0590 |
| Mar 23, 2026 | Mar 23, 2026 | Mar 25, 2026 | $0.0610 |
| Dec 22, 2025 | Dec 22, 2025 | Dec 24, 2025 | $0.1130 |
| Sep 22, 2025 | Sep 22, 2025 | Sep 24, 2025 | $0.1026 |
| Jun 23, 2025 | Jun 23, 2025 | Jun 25, 2025 | $0.0959 |
| Mar 24, 2025 | Mar 24, 2025 | Mar 26, 2025 | $0.1533 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 26, 2024 | $0.1548 |
| Sep 23, 2024 | Sep 23, 2024 | Sep 25, 2024 | $0.1947 |
| Jun 24, 2024 | Jun 24, 2024 | Jun 26, 2024 | $0.1557 |
| Mar 18, 2024 | Mar 19, 2024 | Mar 21, 2024 | $0.1730 |
| Dec 18, 2023 | Dec 19, 2023 | Dec 21, 2023 | $0.1744 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 23.30% / 21.13% | Sharpe 1Y / 3Y | 1.29 / 0.851 |
| Max drawdown 1Y / 3Y | -16.19% / -23.56% | Sortino 1Y | 1.99 |
| Beta vs S&P 500 (3Y) | 0.754 | Correlation vs S&P 500 (1Y) | 0.412 |
| Downside deviation 1Y | 15.11% | Risk-free rate used | 4.09% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 16, 2026. Formulas →
Liquidity
| Volume today | 137.72K | Average volume | 146.17K |
| AUM | $444.2M | Premium/Discount | +1.43% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$3.0M | -0.67% | $447.2M → $444.2M |
| 1 Month | -$113.3M | -19.17% | $590.9M → $444.2M |
| 1 Week | $2.3M | +0.50% | $453.4M → $444.2M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for XPH
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.